MaaT Pharma SA

Paris Stock Exchange MAAT.PA

MaaT Pharma SA Price to Sales Ratio (P/S) on January 14, 2025: 48.41

MaaT Pharma SA Price to Sales Ratio (P/S) is 48.41 on January 14, 2025, a 15.90% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

MaaT Pharma SA 52-week high Price to Sales Ratio (P/S) is 57.28 on March 13, 2024, which is 18.32% above the current Price to Sales Ratio (P/S).
MaaT Pharma SA 52-week low Price to Sales Ratio (P/S) is 38.72 on January 19, 2024, which is -20.01% below the current Price to Sales Ratio (P/S).
MaaT Pharma SA average Price to Sales Ratio (P/S) for the last 52 weeks is 46.59.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Paris Stock Exchange: MAAT.PA

MaaT Pharma SA

CEO	Mr. Herve Affagard
IPO Date	Nov. 8, 2021
Location	France
Headquarters	70 Avenue Tony Garnier
Employees	54
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

Key trends

Past 5 years